AdAlta (ASX:1AD)
ASX announcement history & article coverage
Transparent by design.
Announcments by AdAlta (ASX:1AD) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
BZDS1901 special access scheme launch in China
AdAlta partner approved to provide CAR-T therapy for advanced mesothelioma in China under special access scheme
Appendix 4G and Corporate Governance Statement
Annual Report to shareholders
AdAlta advances cellular immunotherapy pipeline, secures first asset, raises A$5.3M, reports FY2026 loss
Preliminary Final Report
Investor presentation
EW-001 IIT study overall survival update
AdAlta reports ongoing patient survival and promising response rates in EW-001 mesothelioma trial
2 year survival milestone for EW-001 patient
AdAlta's EW-001 CAR-T Therapy Shows Durable Complete Responses in Advanced Mesothelioma
Quarterly Appendix 4C and Activities Report
AdAlta secures EW-001 CAR-T rights, advances manufacturing and FDA engagement, raises A$2.5M, and boosts AI capabilities
ISCTANZ2026 presentation and poster
ISCT poster awarded oral presentation
Cleansing Notice
Application for quotation of securities - 1AD
Application for quotation of securities - 1AD
Oktopi AI collaboration for research efficiency
AdAlta partners with Oktopi to boost AI-driven medicine development and strategic growth
Second BZDS1901 milestone paid
AdAlta completes milestone payment for BZDS1901 CAR-T, advancing manufacturing and FDA engagement
Cleansing Notice
Application for quotation of securities - 1AD
Results of Meeting
Confirmation of results of Prospectus Offer